Peng Li, Zhu Ni, Wang Dan, Zhou Yanhong, Liu Yifei
School of Stomatology and Ophthalmology, Xianning Medical College, Hubei University of Science and Technology, Xianning, People's Republic of China.
Int J Gen Med. 2022 Jun 3;15:5425-5440. doi: 10.2147/IJGM.S353380. eCollection 2022.
Nod-like receptor C4 (NLRC4) is a member of the Nod-like receptor (NLR) family, and its expression mediates the activation of caspase-1 (CASP1). Abnormal expression of NLRC4 and CASP1 is associated with multiple tumors. However, the expression differences, prognostic value and immune correlation of NLRC4 and CASP1 in colorectal cancer (CRC) remain to be determined.
In this study, TCGA, CCLE, HPA, PrognoScan, STRING and GeneMANIA databases were used to analyze differences in expression, prognostic value, genetic alterations and immune cell infiltration of NLRC4 and CASP1 in CRC patients. Then, we further validated the expression of NLRC4 and CASP1 in CRC using immunohistochemistry (IHC).
NLRC4 and CASP1 were expressed low in CRC tissues and CRC cell lines. The expression of NLRC4 was significantly related to the patient's gender and lymph node metastasis. NLRC4 and CASP1 down-regulated expression was observably correlated with poor survival and diverse immune cells infiltration in CRC patients. NLRC4 and CASP1 have a gene mutation alteration. NLRC4 and CASP1 had a significant positive correlation in CRC.
This study will provide new ideas for the prognosis and treatment in CRC. NLRC4 and CASP1 are expected to be novel biomarkers and potential immunotherapy targets in CRC patients.
NOD样受体C4(NLRC4)是NOD样受体(NLR)家族的成员,其表达介导半胱天冬酶-1(CASP1)的激活。NLRC4和CASP1的异常表达与多种肿瘤相关。然而,NLRC4和CASP1在结直肠癌(CRC)中的表达差异、预后价值和免疫相关性仍有待确定。
在本研究中,使用TCGA、CCLE、HPA、PrognoScan、STRING和GeneMANIA数据库分析CRC患者中NLRC4和CASP1的表达差异、预后价值、基因改变和免疫细胞浸润情况。然后,我们使用免疫组织化学(IHC)进一步验证NLRC4和CASP1在CRC中的表达。
NLRC4和CASP1在CRC组织和CRC细胞系中表达较低。NLRC4的表达与患者的性别和淋巴结转移显著相关。NLRC4和CASP1表达下调与CRC患者的不良生存和多种免疫细胞浸润明显相关。NLRC4和CASP1存在基因突变改变。NLRC4和CASP1在CRC中具有显著的正相关。
本研究将为CRC的预后和治疗提供新思路。NLRC4和CASP1有望成为CRC患者的新型生物标志物和潜在的免疫治疗靶点。